Polish investor invests in “Chimpharm” an additional $ 37 million
The development of the IT infrastructure, the production digitization, the improvement and automation of quality control and quality assurance, the development and design of new medicines are the main objectives of the fourth stage of the investment program of the “Polpharma” international group for 2018-2022, with an investment of 37 million dollars USA. The investor will continue modernization of the largest pharmaceutical production in Kazakhstan, located in the South-Kazakhstan oblast at the oldest pharmaceutical plant in the region - “Chimpharm” JSC.
At the present time, Kazakhstan is working on the adoption of elements of “Industry 4.0". Adoption of digital technologies in production will become one of the factors of success of Kazakhstan enterprises and will allow to optimize production processes.
“SANTO” company, being a part of the international pharmaceutical group “Polpharma” (Poland), is implementing the largest investment project in the South Kazakhstan oblast to modernize the existing pharmaceutical production “Chimpharm” JSC in accordance with international standards cGMP (eng. Good Manufacturing Practice; Good manufacturing practice).
It is expected that in the period from 2018 to 2022 in the framework of the fourth stage of modernization of the largest Kazakh drug factory “Chimpharm” JSC will build a new laboratory, upgrade the infrastructure, modernize logistics facilities, upgrade equipment for research and development, and in March 2018 a new section of non-sterile solutions was launched.
Significant funds are planned to be used for automation and digitalization of both main and auxiliary production processes, such as: innovative IT-solution in personnel management – “Cloud HR”; “Smart” warehouse management system at production sites, automation system for planning and accounting for maintenance and repair work; planning of human and material resources; automation and management of processes of quality assurance in production, etc.
Polish investors plan to invest about 37 million dollars in the fourth technological modernization of “Chimpharm” JSC, designed for 2018-2022. USA.
“In fact, today, at the plant of “Chimpharm” JSC in the city of Shymkent, construction and modernization of all major production facilities and auxiliary logistic sites have been completed. The investment program will now focus on new projects in the field of digitalization and automation of production and support processes, as well as projects in the field of management and quality control systems.
Since 2009, Kazakhstan has a system of long-term contracts with domestic producers through a single distributor for the supply of medicines for the needs of the health care system. Only “Chimpharm” JSC for today has 5 concluded contracts, according to which we have the opportunity to carry out guaranteed supplies for medical institutions of the Republic of Kazakhstan. Long-term contracts allow investors to get contracted sales volume, which stimulates the creation of new modern and competitive pharmaceuticals. Investors also receive preferences through investment contracts with the Ministry of Investment and Development, domestic producers can rely on soft loans from the Development Bank of Kazakhstan. In Kazakhstan, various tools and mechanisms have been developed to support domestic producers and investors. “Chimpharm” JSC uses these tools with the maximum possible efficiency” says Rustam Baigarin, the Director of the plant of “Chimpharm” JSC.
Currently, the company employs more than 1,200 qualified employees, some of whom have been trained at foreign enterprises of the “Polpharma” group and in countries that are the world leaders in the pharmaceutical industry (equipment manufacturers). The company registered 115 drugs covering 12 pharmacological groups. Thus, products of the parenteral form (injections and infusions), solid form (tablets, capsules, sachets powders), aseptic powders of antibiotics, non-sterile liquids and syrups are produced.
“We are pleased that “Polpharma group” is expanding its presence in the Kazakh pharmaceutical market by introducing innovative technologies into production. This is the fourth wave of modernization of “Chimpharm” JSC, the oldest pharmaceutical enterprise in the republic. “Industry 4.0” elements are being introduced at the manufacture. Thanks to additional reinvestment, new jobs will be created in the South-Kazakhstan oblast,” said Dauletkozha Mamyrov, regional Director of “Kazakh Invest” for SKO.
For reference:
Companies of the POLPHARMAGroup are the leader of the Polish pharmaceutical market. It has 6 production plants, 6 research centers, more than 7,300 employees. One of the 20 leading manufacturers of generic drugs in the world. The sales volume is more than 1 billion US dollars per year. The company's portfolio includes more than 600 products, more than 230 preparations are being developed.
As part of the execution of the instruction of the Head of State, “Kazakh Invest” jointly with the World Bank developed the National Investment Strategy for 2018-2022. The work will be carried out in three directions: improving the investment climate in Kazakhstan; implementation of effective operational measures and development of new approaches to attract investment; privatization and public-private partnership. In the National Strategy, priority sectors for attracting foreign investments (agribusiness, machine building, chemistry and petrochemistry, infrastructure, mining and metallurgy, trade) and 11 priority countries, which account for up to 80% of investments in the world (USA, Russia, Great Britain, Germany , France, Italy, China, Japan, South Korea, Turkey, United Arab Emirates). By 2022 it is expected that the gross inflow of FDI will increase by 1.26 times; the ratio of gross FDI to GDP in 2022 will increase to 19%; FDI focused on increasing efficiency will increase by 1.5 times; the volume of investments in the fixed capital of the non-extractive sector of the economy will increase by 1.46 times; the volume of foreign investment in the fixed capital of the non-primary sector of the economy will increase by 1.5 times.
